“Pretty sure he said he will be sending it. He never specified which dose but it would only make sense it’s the 700mg dose since it was double blind trial.”
Why would NP tell shareholders that he’s sending the NASH data to multiple FDAs and 1,000 pharmaceutical companies without first announcing that data? Well, he’s done it before: CD12. He announced the data was unblinded and was being sent to multiple FDAs but he knew at the time of that PR that CD12 had failed. This could be what happened in this case: the 700mg data on 30 patients didn’t meet the endpoints of the trial.
Another scenario: Amarex has the 700mg data as they are listed as the sponsor on clinicaltrials.gov. That’s a big issue as it appears CYDY may not be able to pay the cash bond, which they said themselves in the 10q.
“To obtain the bond, the Company must tender $6.5 million in cash as collateral to the surety issuing the bond. If the Company is unable to provide the collateral in a timely fashion, its ability to review the databases and related information that Amarex holds may be delayed, potentially for several months or longer, resulting in additional delays in completion of the BLA resubmission process.”
Unfortunately, what makes sense to you doesn’t make sense in Nader land.
News 
Market Data 
Discover 
